Safety and PK of BMS-986142 in Healthy Subjects

Phase 1, randomised, double-blind trial of BMS-986142 in rheumatoid arthritis (RA) and Sjogren's syndrome (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence, potential significance, and clinical importance of adverse events after single dose at 8 days and Incidence, potential significance, and clinical importance of adverse events after multiple doses at 19 days. Started Sep 2014; status: completed.